DSM Biologics and Argenes, Inc., headquartered in Tokyo, Japan, have signed a biopharmaceutical manufacturing agreement. Under the terms of the agreement, DSM will provide Argenes with full process development services, analytical development services and manufacturing batches for Argenes’ Anti-Fas IgM monoclonal antibody. The services will be provided out of DSM Biologics’ FDA-approved manufacturing facility in Groningen, The Netherlands. Argenes’ Anti-FAS IgM monoclonal antibody is being developed as an anti-rheumatic agent.

“The agreement is a further reinforcement of the strong and mutually beneficial relationship between Argenes and DSM Biologics. We gladly entrust DSM with the execution of this agreement that is crucial for the success of our Anti-Fas IgM monoclonal antibody,” said Kamishohara, president and chief executive officer of Argenes.

“DSM Biologics is very pleased to be involved in this exciting project. The agreement is a clear recognition of the value that DSM Biologics has brought, and will continue to bring to Argenes, an important client for DSM Biologics,” said Terry Novak, chief marketing officer of DSM Biologics.